Schweiz - Deutsch - Swissmedic (Swiss Agency for Therapeutic Products)

astrazeneca ag - tezepelumabum - injektionslösung in einer fertigspritze - tezepelumabum 210 mg, prolinum, acidum aceticum glaciale, polysorbatum 80, natrii hydroxidum q.s. ad ph, aqua ad iniectabile, ad solutionem pro 1.91 ml. - zusatztherapie bei schwerem asthma - biotechnologika

Europäische Union - Deutsch - EMA (European Medicines Agency)

astrazeneca ab - tezepelumab - asthma - medikamente für obstruktive atemwegserkrankungen, - tezspire is indicated as an add-on maintenance treatment in adults and adolescents 12 years and older with severe asthma who are inadequately controlled despite high dose inhaled corticosteroids plus another medicinal product for maintenance treatment.

Schweiz - Deutsch - Swissmedic (Swiss Agency for Therapeutic Products)

astrazeneca ag - tezepelumabum - injektionslösung in einem fertigpen - tezepelumabum 210 mg, prolinum, acidum aceticum glaciale, polysorbatum 80, natrii hydroxidum q.s. ad ph, aqua ad iniectabile, ad solutionem pro 1.91 ml. - zusatztherapie bei schwerem asthma - biotechnologika

Europäische Union - Deutsch - EMA (European Medicines Agency)

swedish orphan biovitrum ab (publ) - emapalumab - immune system diseases - gamifant is indicated for the treatment of paediatric patients aged under 18 years with primary haemophagocytic lymphohistiocytosis (hlh).

Europäische Union - Deutsch - EMA (European Medicines Agency)

astrazeneca ab - durvalumab - karzinom, nicht kleinzellige lunge - antineoplastische mittel - non-small cell lung cancer (nsclc)imfinzi as monotherapy is indicated for the treatment of locally advanced, unresectable non small cell lung cancer (nsclc) in adults whose tumours express pd-l1 on ≥ 1% of tumour cells and whose disease has not progressed following platinum based chemoradiation therapy (see section 5. imfinzi in combination with tremelimumab and platinum-based chemotherapy is indicated for the first-line treatment of adults with metastatic nsclc with no sensitising egfr mutations or alk positive mutations. small cell lung cancer (sclc)imfinzi in combination with etoposide and either carboplatin or cisplatin is indicated for the first-line treatment of adults with extensive-stage small cell lung cancer (es-sclc). biliary tract cancer (btc)imfinzi in combination with gemcitabine and cisplatin is indicated for the first line treatment of adults with unresectable or metastatic biliary tract cancer (btc). hepatocellular carcinoma (hcc)imfinzi in combination with tremelimumab is indicated for the first line treatment of adults with advanced or unresectable hepatocellular carcinoma (hcc).